Back to search results

Peer Recovery Support for Opioid Use Disorder Treatment

This study is looking at whether adding peer recovery support (help from someone with their own experience of addiction and recovery) can help people stay in treatment for opioid use disorder. You might be able to join if you are 18 or older, have started medication for opioid use disorder in the last 45 days at a Geisinger clinic, and are willing to give informed consent. The study will compare people who receive standard care plus peer support to those who receive standard care alone. The main goal is to see if peer support helps people stay in treatment for 6 months.

Study design
This study plans to enroll 218 participants. It will compare two groups: one receiving standard care plus peer recovery support, and another receiving standard care alone.
What's involved
If you join, you would meet one-on-one with a peer recovery specialist over a 6-month period.
Compensation
Not stated in the trial record.
Follow-up
The study will measure how long participants stay in treatment for up to 180 days (about 6 months) from when they started medication.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07197801

Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Disorder Treatment

Recruiting
NAAges 18–89InterventionalHealth services
Geisinger Clinic
~218 participants
Updated 2026-02-18 on ClinicalTrials.gov
What's tested:Peer recovery support to enhance patient engagement in medication for opioid use disorder treatment

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
6-month treatment retention
Measured over 180 days from initiation of medication treatment for opioid use disorder
+1 more outcome measured

Conditions

Opioid Use Disorder

Explore related trials

Opioid Use Disorder

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Melissa Poulsen, PhD · PRINCIPAL_INVESTIGATOR · Geisinger Clinic

Who to contact

Project Manager
[email protected]
1-866-910-6486, Option 3
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult ≥ 18 years of age
Initiated medication for opioid use disorder treatment in past 45 days in a Geisinger outpatient clinic
Willing and able to give informed consent

Exclusion

Received medication for opioid use disorder treatment at a Geisinger outpatient clinic in the 90-day period prior to the treatment initiation date
Not proficient in English

What this trial measures

  • 6-month treatment retention180 days from initiation of medication treatment for opioid use disorder

    Data will come from the electronic health records. Retention will be defined as a participant not having a lapse in days' supply of medication for opioid use disorder treatment (buprenorphine, buprenorphine-naloxone, or naltrexone) within the 6-month follow-up period that is greater than 30 days.

  • Length of time in treatment180 days from initiation of medication treatment for opioid use disorder

    Data will come from the electronic health records. Length of time in treatment will be determined by summing days' supply of consecutive orders for medications for opioid use disorder treatment(buprenorphine, buprenorphine- naloxone, or naltrexone). Treatment will be considered ended if a participant has a gap in supply of more than 30 days.